CORDIS
EU research results

CORDIS

English EN

Ration design and standardized evaluation of novel genetic vaccines.

Project information

Grant agreement ID: 5246

  • Start date

    1 January 2005

  • End date

    30 June 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 10 255 436

  • EU contribution

    € 8 269 442

Coordinated by:

CENTRE NATIONAL DE LE RECHERCHE SCIENTIFIQUE

France

Objective

Recombinant viral vectors and virus-like particles are considered the most promising vehicles to deliver antigens in prophylactic and therapeutic vaccines against infectious diseases and cancer. Several potential vaccine designs exist but their cost-effective development cruelly lacks a standardised evaluation system. On these grounds, COMPUVAC is devoted to (i) rational development of a novel platform of genetic vaccines and (ii) standardisation of vaccine evaluation. COMPUVAC assembles a platform of viral vectors and virus-like particles that are among today's most promising vaccine candidates and that are backed up by the consortium's complementary expertise and intellectual property, including SMEs focusing on vaccine development. COMPUVAC recognises the lack of uniform means for side-by-side qualitative and quantitative vaccine evaluation and will thus standardise the evaluation of vaccine efficacy and safety by using "gold standard" tools, molecular and cellular methods in virology and immunology, and algorithms based on genomic and proteomic information. "Gold standard" algorithms for intelligent interpretation of vaccine efficacy and safety will be built into COMPUVAC's interactive Genetic Vaccine Decision Support System, which should generate (i) vector classification according to induced immune response quality, accounting for gender and age, (ii) vector combination counsel for prime-boost immunisations, and (iii) vector safety profile according to genomic analysis. The knowledge assembled from these studies will be applied to the development of vaccines against Hepatitis C Virus. As end products, our vector platform and "gold standard" tools, methods and algorithms will be available to the scientific and industrial communities as a toolbox and interactive database which standardised nature should contribute to cost-effective development of novel vaccines with validated efficacy and safety profile.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

CENTRE NATIONAL DE LE RECHERCHE SCIENTIFIQUE

Address

3 Rue Michelange
Paris

France

Participants (18)

UNIVERSITÉ PIERRE ET MARIE CURIE

France

ASLA BIOTECH LTD.

Latvia

POZNAN UNIVERSITY OF TECHNOLOGY

Poland

LUDWIG-MAXIMILIANS-UNIVERITÄT MÜNCHEN

Germany

INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE

France

CYTOS BIOTECHNOLOGY AG

Switzerland

EPIXIS

France

UNIVERSITÉ CLAUDE BERNARD LYON I

France

UNIVERSITÄTSKLINIKUM ULM

Germany

INSTITUTE PASTEUR HELLENIQUE

Greece

ERASMUS MC ROTTERDAM

Netherlands

BIOMEDICAL RESEARCH AND STUDY CENTRE

Latvia

INSTITUTE OF BIOTECHNOLOGY

Lithuania

UNIVERSITY OF ZURICH

Switzerland

UNIVERSITY OF CAPE TOWN

South Africa

INSTITUT PASTEUR

France

UNIVERSITÉ DE GENÈVE

Switzerland

KAROLINSKA INSTITUTET

Sweden

Project information

Grant agreement ID: 5246

  • Start date

    1 January 2005

  • End date

    30 June 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 10 255 436

  • EU contribution

    € 8 269 442

Coordinated by:

CENTRE NATIONAL DE LE RECHERCHE SCIENTIFIQUE

France